Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion to Expand Rare Disease Portfolio

Major Acquisition Brings First-in-Class Rare Disease Therapy to Neurocrine

Neurocrine Biosciences has announced its agreement to acquire Soleno Therapeutics for $2.9 billion in cash, marking one of 2026’s largest biotechnology transactions. The deal, valued at $53 per share, represents a 34% premium over Soleno’s closing price and brings Neurocrine its first metabolic disease therapy.

Legal powerhouses guided both sides of the transaction. Cooley LLP advised Neurocrine Biosciences on the acquisition, while Wilson Sonsini Goodrich & Rosati PC provided legal counsel to Soleno. Goldman Sachs served as Neurocrine’s financial advisor, with Centerview Partners and Guggenheim Securities advising Soleno.

Vykat XR Demonstrates Strong Commercial Performance in Debut Year

The centerpiece of this acquisition is Soleno’s breakthrough therapy Vykat XR, which received FDA approval in March 2025 as the first and only treatment for hyperphagia in patients with Prader-Willi syndrome. Since its commercial launch, the drug has exceeded expectations with $190 million in revenue for 2025, including $92 million in the fourth quarter alone.

Prader-Willi syndrome affects approximately 10,000 to 20,000 patients in the United States, causing extreme and persistent hunger that can lead to life-threatening complications. Previously, no specific pharmacological treatment existed for the condition’s defining symptom of hyperphagia, making Vykat XR a transformative therapy for this patient population.

Strategic Expansion Into High-Growth Therapeutic Areas

For Neurocrine, this acquisition represents a strategic diversification beyond its core neuroscience franchise. The company’s existing portfolio includes Ingrezza, which generated $2.5 billion in revenue in 2025, and Crenessity, approved for congenital adrenal hyperplasia in late 2024. Adding Vykat XR creates a third revenue pillar in the rapidly expanding rare disease market.

The transaction is expected to close within 90 days, subject to standard regulatory approvals and closing conditions. Both companies’ boards have unanimously approved the deal, which Neurocrine will fund through cash on hand supplemented by modest pre-payable debt financing.

Financial and Regulatory Implications for Healthcare Organizations

This acquisition reflects broader trends in pharmaceutical consolidation, particularly the premium valuations being paid for de-risked rare disease assets. The deal comes as many large pharmaceutical companies face patent cliffs and seek to replenish their pipelines with commercially proven therapies.

For healthcare organizations treating patients with rare genetic disorders, this transaction may influence future pricing and access considerations. Vykat XR currently carries an annual price of approximately $466,000, though early reimbursement dynamics have reportedly exceeded expectations according to physician surveys.

The integration of Soleno’s commercial operations into Neurocrine’s existing infrastructure could also affect distribution networks and patient access programs. Healthcare providers should monitor how this consolidation impacts their ability to serve patients with Prader-Willi syndrome and related rare conditions.

Healthcare organizations navigating rare disease therapeutics and pharmaceutical market consolidation can benefit from specialized guidance. Contact James Moore’s healthcare practice team to discuss how these developments may impact your organization.

All content provided in this article is for informational purposes only. Matters discussed in this article are subject to change. For up-to-date information on this subject please contact a James Moore professional. James Moore will not be held responsible for any claim, loss, damage or inconvenience caused as a result of any information within these pages or any information accessed through this site.